Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambient air pollution and risk of respiratory tract infections in low- and middle-income countries: a systematic review and meta-analysis.

BMC public health·2026
Same author

Ebola outbreak caused by Bundibugyo virus: challenges and priorities for epidemic preparedness and response.

Lancet (London, England)·2026
Same author

Determinants and gaps influencing zero-dose immunization and maternal Health service utilization in Nigeria: a cross-sectional household survey across six Nigerian states.

Global health action·2026
Same author

Clade-specific ophthalmic manifestations of mpox: an umbrella review and meta-analysis of systematic reviews.

The British journal of ophthalmology·2025
Same author

Enhancing the use of routine program data for immunization decision-making: The role of coincidence analysis in localized learning and adaptation.

Human vaccines & immunotherapeutics·2025
Same author

Metals exposure and biomarkers of liver damage: a systematic review and meta-analysis of observational studies.

Reviews on environmental health·2025

Related Experiment Video

Updated: Jul 3, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

Adjunctive therapies for AIDS dementia complex.

Olalekan A Uthman1, Jubril O Abdulmalik

  • 1Save the Youth Initiative, P. O. Box 5146, Ilorin, Kwara State, Nigeria, 240-001. uthlekan@yahoo.com

The Cochrane Database of Systematic Reviews
|July 23, 2008
PubMed
Summary

Adjunctive therapies for AIDS dementia complex (ADC) show no significant cognitive benefits. While safe and well-tolerated, these treatments do not improve outcomes for HIV-1 patients with ADC.

Related Experiment Videos

Last Updated: Jul 3, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Clinical Trials

Background:

  • AIDS dementia complex (ADC) remains a significant complication of HIV-1 infection, persisting despite advanced antiretroviral therapies.
  • ADC contributes to substantial patient morbidity and is associated with reduced survival rates in severe cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of adjunctive therapies for managing AIDS dementia complex in adults.
  • To synthesize evidence from randomized controlled trials on the impact of supplementary treatments on cognitive function and quality of life in ADC patients.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases including MEDLINE, EMBASE, and Cochrane HIV/AIDS registers up to February 2007.
  • Included were randomized controlled trials comparing adjunctive therapies against placebo or no treatment in adults diagnosed with AIDS dementia complex.
  • Data on neurocognitive performance, adverse effects, tolerability, and mortality were extracted and analyzed from ten eligible phase 2 trials.

Main Results:

  • Ten trials with 711 participants were analyzed, assessing various adjunctive therapies for ADC.
  • No statistically significant differences were observed in neuropsychological test scores between treatment and placebo groups.
  • Furthermore, no significant differences were found in medication adherence, adverse effects, or all-cause mortality between the groups.

Conclusions:

  • Current evidence does not support the use of adjunctive therapies to improve cognitive performance or quality of life in patients with AIDS dementia complex.
  • Despite the lack of demonstrated efficacy, the reviewed adjunctive therapies were found to be safe and well-tolerated by patients.
  • Further research may be needed to identify effective interventions for managing cognitive impairment in HIV-1 infected individuals with ADC.